Americas We will accelerate oncology franchise growth and strengthen our solid business platform in urology. Fiscal 2013 Overview *Sales and year-on-year changes are based on J-GAAP. Net sales in the Americas amounted to US$2,878 million, up 14.6% from  the previous year on a U.S. dollar basis. When converted to yen, with the  impact of foreign exchange rates and other factors, net sales grew  38.2% to ¥288.5 billion. By product, we posted US$450 million in sales of XTANDI, launched in  September 2012, and US$145 million for Myrbetriq, launched a month  later in October 2012. Both of these products contributed to the higher  overall sales in the Americas. In addition, sales of VESIcare continued to  grow, up 2.9% to US$580 million. Our share of the total prescription market  for OAB treatments, including VESIcare and Myrbetriq, expanded further.  Also, revenues from anticancer drug Tarceva increased. However, sales  of Prograf fell due partly to the impact of generics. At the same time, on a  U.S. dollar basis overall sales of the pharmacologic stress agents Adenoscan  and Lexiscan declined, due mainly to the impact of generics on Adenoscan,  despite expanding sales of Lexiscan. Fiscal 2014 Outlook *Sales and year-on-year changes are based on IFRS. We forecast regional sales of US$2,892 million, a year-on-year increase  of 1.0% on a U.S. dollar basis. When converted to yen, the regional sales  are expected to grow 0.8% to ¥289.2 billion. In addition to XTANDI, sales  of the OAB treatments VESIcare and Myrbetriq and revenues from Tarceva  are forecast to continue growing. On the other hand, we anticipate a  decrease in sales of Prograf and overall sales of the pharmacologic stress  agents Adenoscan and Lexiscan, mainly due to the impact of generics. Americas 25.2% Sales by Geographical Area 2014.3 EMEA 23.2% Japan 46.5% Asia & Oceania 5.1% Note: Yen base *Calculated according to the location of sellers *IFRS Net Sales (US$ million) 3,000 2,500 2,000 1,500 1,000 500 0 2012.3 2013.3 2014.3 2015.3 J-GAAP IFRS (Forecast) Astellas Pharma Inc.  _ Annual Report 2014 46